95 related articles for article (PubMed ID: 8271378)
1. [A synthetic peptide "T22" as anti-HIV agents].
Nakashima H; Murakami T
Nihon Rinsho; 1993 Sep; 51 Suppl():146-52. PubMed ID: 8271378
[No Abstract] [Full Text] [Related]
2. The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule.
Weeks BS; Nomizu M; Otaka A; Weston CA; Okusu A; Tamamura H; Yamamoto N; Fujii N
Biochem Biophys Res Commun; 1995 Oct; 215(2):626-31. PubMed ID: 7488001
[TBL] [Abstract][Full Text] [Related]
3. Interaction of an anti-HIV peptide, T22, with gp120 and CD4.
Tamamura H; Otaka A; Murakami T; Ishihara T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Biochem Biophys Res Commun; 1996 Feb; 219(2):555-9. PubMed ID: 8605026
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of an anti-HIV peptide, T22.
Tamamura H; Murakami T; Masuda M; Otaka A; Takada W; Ibuka T; Nakashima H; Waki M; Matsumoto A; Yamamoto N
Biochem Biophys Res Commun; 1994 Dec; 205(3):1729-35. PubMed ID: 7811258
[TBL] [Abstract][Full Text] [Related]
5. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.
Nakashima H; Masuda M; Murakami T; Koyanagi Y; Matsumoto A; Fujii N; Yamamoto N
Antimicrob Agents Chemother; 1992 Jun; 36(6):1249-55. PubMed ID: 1384424
[TBL] [Abstract][Full Text] [Related]
6. A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.
Jenssen H; Andersen JH; Mantzilas D; Gutteberg TJ
Antiviral Res; 2004 Nov; 64(2):119-26. PubMed ID: 15498607
[TBL] [Abstract][Full Text] [Related]
7. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).
Masuda M; Nakashima H; Ueda T; Naba H; Ikoma R; Otaka A; Terakawa Y; Tamamura H; Ibuka T; Murakami T
Biochem Biophys Res Commun; 1992 Dec; 189(2):845-50. PubMed ID: 1472056
[TBL] [Abstract][Full Text] [Related]
8. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence.
Jiang S; Lin K
Pept Res; 1995; 8(6):345-8. PubMed ID: 8838418
[TBL] [Abstract][Full Text] [Related]
9. An anti-HIV peptide, T22, forms a highly active complex with Zn(II).
Tamamura H; Otaka A; Murakami T; Ibuka T; Sakano K; Waki M; Matsumoto A; Yamamoto N; Fujii N
Biochem Biophys Res Commun; 1996 Dec; 229(2):648-52. PubMed ID: 8954952
[TBL] [Abstract][Full Text] [Related]
10. [Antiviral compounds: current approaches for development].
Suzutani T; Azuma M
Nihon Rinsho; 1993 Jul; 51(7):1907-14. PubMed ID: 8366615
[TBL] [Abstract][Full Text] [Related]
11. Prediction of activity, synthesis and biological testing of anti-HSV active peptides.
Jenssen H; Gutteberg TJ; Rekdal Ø; Lejon T
Chem Biol Drug Des; 2006 Jul; 68(1):58-66. PubMed ID: 16923027
[TBL] [Abstract][Full Text] [Related]
12. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II).
Otaka A; Tamamura H; Terakawa Y; Masuda M; Koide T; Murakami T; Nakashima H; Matsuzaki K; Miyajima K; Ibuka T
Biol Pharm Bull; 1994 Dec; 17(12):1669-72. PubMed ID: 7735216
[TBL] [Abstract][Full Text] [Related]
13. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
Wild C; Oas T; McDanal C; Bolognesi D; Matthews T
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10537-41. PubMed ID: 1438243
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity.
Tamamura H; Murakami T; Horiuchi S; Sugihara K; Otaka A; Takada W; Ibuka T; Waki M; Yamamoto N; Fujii N
Chem Pharm Bull (Tokyo); 1995 May; 43(5):853-8. PubMed ID: 7553971
[TBL] [Abstract][Full Text] [Related]
15. Specificity of HIV inhibition by modified antisense oligonucleotides.
Abramova T; Blinov V; Vlassov V; Gorn V; Zarytova V; Ivanova E; Konevets D; Plyasunova O; Pokrovsky A; Sandakhchiev L
Nucleic Acids Symp Ser; 1991; (24):283. PubMed ID: 1841341
[No Abstract] [Full Text] [Related]
16. NMR structure of mussel mytilin, and antiviral-antibacterial activities of derived synthetic peptides.
Roch P; Yang Y; Toubiana M; Aumelas A
Dev Comp Immunol; 2008; 32(3):227-38. PubMed ID: 17628674
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1.
Dettin M; Pasquato A; Scarinci C; Zanchetta M; De Rossi A; Di Bello C
J Med Chem; 2004 Jun; 47(12):3058-64. PubMed ID: 15163187
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance.
Tamamura H; Kuroda M; Masuda M; Otaka A; Funakoshi S; Nakashima H; Yamamoto N; Waki M; Matsumoto A; Lancelin JM
Biochim Biophys Acta; 1993 May; 1163(2):209-16. PubMed ID: 8490053
[TBL] [Abstract][Full Text] [Related]
19. CD4(81-92)-based peptide derivatives. Structural requirements for blockade of HIV infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro.
Rausch DM; Lifson JD; Padgett MP; Chandrasekhar B; Lendvay J; Hwang KM; Eiden LE
Biochem Pharmacol; 1992 Apr; 43(8):1785-96. PubMed ID: 1575773
[TBL] [Abstract][Full Text] [Related]
20. [3'-Fluoro-deoxythymidine-5-fluorophosphate--an effective inhibitor of reproduction of human immunodeficiency virus in cell cultures].
Arzumanov AA; Diatkina NB; Kukhanova MK; Kraevskiĭ AA; Semchenko FM; Eremin OG; Martynov BI
Bioorg Khim; 1993 Oct; 19(10):978-80. PubMed ID: 8274172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
